Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting

Oct 11, 2010, 08:00 ET from Optimer Pharmaceuticals, Inc.

SAN DIEGO, Oct. 11 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced two oral presentations from studies related to lead developmental product candidate, fidaxomicin, will be presented at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at the Vancouver Convention Center in Vancouver, British Columbia, Canada on October 21-24, 2010.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"Efficacy and Safety of Fidaxomicin vs. Vancomycin in Clostridium difficile Infection in 2 Randomized Controlled Trials with 1105 Patients"

Oral Presentation: Derrick Crook, M.D.

Saturday, October 23, 2010 3:30pm Pacific Time

Session: 146 Oral Abstract Session: Clostridium difficile

Presentation number: 1417

"Categorization of Patients in a Large Multicenter Study of Clostridium difficile Infection Using the ATLAS Bedside Scoring System, and Correlation with Both Cure and Recurrence"

Oral Presentation: Mark A. Miller, M.D.

Saturday, October 23, 2010 2:00pm Pacific Time

Session: 146 Oral Abstract Session: Clostridium difficile

Presentation number: 1411

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates under development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI) and we recently initiated a rolling submission of our NDA filing to the FDA, and have filed a MAA to the EMA (Europe).  Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea and we plan to have a NDA submitted to the FDA in the first quarter of 2011.   Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.

Christina Donaghy, Corporate Communications Manager

John D. Prunty, Chief Financial Officer & VP Finance

858-909-0736

Canale Communications, Inc.

Jason I. Spark, Senior Vice President

619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.



RELATED LINKS

http://www.optimerpharma.com